NCT00510887 - Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

September 30, 2013

Conditions

Lymphoma, Follicular

Interventions

DRUG

Bortezomib

Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle

DRUG

Rituximab

Rituximab 375 mg/m2 IV on day 1

DRUG

Fludarabine

Fludarabine 25 mg/m2 IV on days 1,2,3

DRUG

Mitoxantrone

Mitoxantrone 10 mg/m2 IV on day 2

DRUG

Dexamethasone

Dexamethasone 20 mg orally on days 1,2,3,4,5

Trial Locations (1)

Duke University Medical Center, Durham